Blue Sky Asset Management LLC increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 180.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,210 shares of the biopharmaceutical company’s stock after buying an additional 3,998 shares during the period. Blue Sky Asset Management LLC’s holdings in Agios Pharmaceuticals were worth $320,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. C WorldWide Group Holding A S acquired a new position in Agios Pharmaceuticals during the first quarter worth $105,000. Bank of Montreal Can raised its position in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares during the period. Russell Investments Group Ltd. raised its position in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares during the period. Advantage Investment Management LLC raised its position in Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares during the period. Finally, Soros Fund Management LLC acquired a new position in Agios Pharmaceuticals during the first quarter worth $228,000. 84.53% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 60.56 on Thursday. The company has a 50-day moving average of $56.81 and a 200 day moving average of $51.69. Agios Pharmaceuticals, Inc. has a 12-month low of $35.84 and a 12-month high of $67.74. The firm’s market cap is $2.92 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by $0.21. The company had revenue of $11.30 million for the quarter, compared to analysts’ expectations of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 75.48% and a negative net margin of 502.12%. The business’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.47) EPS. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post ($6.90) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Blue Sky Asset Management LLC Increases Position in Agios Pharmaceuticals, Inc. (AGIO)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/blue-sky-asset-management-llc-increases-position-in-agios-pharmaceuticals-inc-agio/1467233.html.

A number of research analysts have weighed in on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, June 11th. ValuEngine raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 28th. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 18th. Finally, Cann reissued a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, April 19th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $68.67.

In other news, CEO David P. Schenkein sold 27,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $179,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Biller sold 4,292 shares of the stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $55.00, for a total transaction of $236,060.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,120 shares of company stock worth $4,557,207. 10.55% of the stock is currently owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.